Showing results (61-70 of 280) with videos related to

Sort By:
Pageof 28
Clinical Genitourinary Cancer|October 9, 2012
Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitorsJames D Turnbull, Julien Cobert, Tracy Jaffe, et al.
Clinical Prostate Cancer|March 26, 2004
Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancerSean R Downing, Kristen T Hennessy, Miyako Abe, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survivalAndrew J Armstrong, Ian F Tannock, Ronald de Wit, et al.
BJUI Compass|October 21, 2022
Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancerTomasz M Beer, Neal Shore, Alicia Morgans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology OutcomesJulie Nonnekens, Lauren A Byers, Aman Chauhan, et al.
Prostate Cancer and Prostatic Diseases|September 3, 2021
Racial disparities in prostate cancer among black men: epidemiology and outcomesIlkania M Chowdhury-Paulino, Caroline Ericsson, Randy Vince, et al.
Future Oncology (London, England)|August 30, 2023
Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?Stephen J Freedland, Krishnan Ramaswamy, Ahong Huang, et al.
Cancer Medicine|October 13, 2022
Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference surveyDaniel J George, Ateesha F Mohamed, Jui-Hua Tsai, et al.
Future Oncology (London, England)|October 13, 2022
Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?Daniel J George, Krishnan Ramaswamy, Ahong Huang, et al.
Genomics|March 11, 2021
Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome AtlasMuthana Al Abo, Terry Hyslop, Xiaodi Qin, et al.
Pageof 28